
USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$486.92M
Market Cap
-
P/E Ratio
-0.71
EPS
$10.42
52 Week High
$3.19
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$39K |
| Total Revenue | $0 |
| Cost Of Revenue | $39K |
| Costof Goods And Services Sold | $39K |
| Operating Income | -$27M |
| Selling General And Administrative | $7.4M |
| Research And Development | $19M |
| Operating Expenses | $27M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $39K |
| Income Before Tax | -$24M |
| Income Tax Expense | $30K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$27M |
| Ebitda | -$27M |
| Net Income | -$24M |
| Field | Value (USD) |
|---|---|
| Total Assets | $46M |
| Total Current Assets | $45M |
| Cash And Cash Equivalents At Carrying Value | $3M |
| Cash And Short Term Investments | $3M |
| Inventory | - |
| Current Net Receivables | $236K |
| Total Non Current Assets | $1.7M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $41M |
| Other Current Assets | $227K |
| Other Non Current Assets | - |
| Total Liabilities | $5.6M |
| Total Current Liabilities | $5.4M |
| Current Accounts Payable | $940K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $103K |
| Total Non Current Liabilities | $237K |
| Capital Lease Obligations | $340K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $340K |
| Other Current Liabilities | $4.3M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $41M |
| Treasury Stock | - |
| Retained Earnings | -$140M |
| Common Stock | - |
| Common Stock Shares Outstanding | $40M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$39K |
| Total Revenue | $0 |
| Cost Of Revenue | $39K |
| Costof Goods And Services Sold | $39K |
| Operating Income | -$27M |
| Selling General And Administrative | $7.4M |
| Research And Development | $19M |
| Operating Expenses | $27M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $39K |
| Income Before Tax | -$24M |
| Income Tax Expense | $30K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$27M |
| Ebitda | -$27M |
| Net Income | -$24M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Minneapolis, Minnesota, focused on developing innovative therapies for neurological and kidney diseases. Its lead product candidate, DM199, aims to enhance renal function in patients with diabetic kidney disease, addressing significant unmet medical needs in this patient population. With a promising pipeline and a strong commitment to clinical advancement, DiaMedica is well-positioned to deliver transformative treatment options that could significantly improve patient outcomes in the biopharmaceutical landscape. The company's strategic approach underscores its potential for growth and impact in the healthcare sector.